Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate
Brief Summary: The only trial in participants who are methotrexate-inadequate responders and have active Rheumatoid Arthritis, in which gadolinium-enhanced Magnetic Resonance Imaging; Bone Mineral Density; and biochemical markers of bone, cartilage, and synovial tissue metabolism are used to evaluate early effects (4 months) of Abatacept on inflammation/structural damage. Study will provide valuable mechanism-of-action information on how Abatacept exerts its effects (including on bone) through new techniques.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
B: Arm Label: Placebo Plus Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Other: Placebo | Arm Label: Rituximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: MabThera/Rituxan, Drug: Methotrexate | Intervention Type: DRUG; Name: MabThera/Rituxan; Assigned to Arm(s): Rituximab plus Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo Plus Methotrexate, Rituximab plus Methotrexate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Plus Methotrexate
C: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: BMS-945429 Placebo, Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 5; Type: EXPERIMENTAL; Interventions: Biological: BMS-945429, Drug: Methotrexate Placebo, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 6; Type: EXPERIMENTAL; Interventions: Biological: BMS-945429, Drug: Methotrexate Placebo, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 7; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Adalimumab | Intervention Type: DRUG; Name: BMS-945429 Placebo; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: BMS-945429; Assigned to Arm(s): Arm 4 | Intervention Type: BIOLOGICAL; Name: BMS-945429; Assigned to Arm(s): Arm 3, Arm 6 | Intervention Type: BIOLOGICAL; Name: BMS-945429; Assigned to Arm(s): Arm 1, Arm 4 | Intervention Type: BIOLOGICAL; Name: BMS-945429; Assigned to Arm(s): Arm 2, Arm 5 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Arm 2, Arm 3, Arm 4, Arm 7 | Intervention Type: DRUG; Name: Methotrexate Placebo; Assigned to Arm(s): Arm 5, Arm 6 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Arm 5, Arm 6 | Intervention Type: DRUG; Name: Adalimumab Placebo; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4, Arm 5, Arm 6 | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Arm 7
D: Arm Label: Abatacept + Methotrexate (Double-blind period); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo + Methotrexate (Double-blind period); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate (Double-blind period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate (Double-blind period)

Answer: D